Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR3680 plus fluzoparib in metastatic castration-resistant prostate cancer
CTR20190607Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rezvilutamide, fluzoparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hengrui Therapeutics. Started Mar 2019; status: terminated.
02
Drugs
rezvilutamidefluzoparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20190607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190607.